Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
暂无分享,去创建一个
[1] C. Parsons,et al. Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.
[2] M. MacDonald,et al. Huntingtin: Alive and Well and Working in Middle Management , 2003, Science's STKE.
[3] M. Berridge. Neuronal Calcium Signaling , 1998, Neuron.
[4] Christopher A Ross,et al. Widespread expression of Huntington's disease gene (IT15) protein product , 1995, Neuron.
[5] M. Bosma,et al. The Type 1 Inositol 1,4,5-Trisphosphate Receptor Gene Is Altered in the opisthotonos Mouse , 1997, The Journal of Neuroscience.
[6] A. Tobin,et al. Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.
[7] P. Mcgeer,et al. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.
[8] Xiao-Jiang Li,et al. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.
[9] A. Joyner,et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.
[10] L. Raymond,et al. Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.
[11] Erich E Wanker,et al. The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.
[12] Jane S. Paulsen,et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.
[13] P. Mcgeer,et al. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract , 1978, Brain Research.
[14] J. Coyle,et al. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.
[15] Christopher A Ross,et al. Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.
[16] K. Mikoshiba,et al. 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. , 1997, Journal of biochemistry.
[17] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[18] M. Madesh,et al. Calcium signaling and apoptosis. , 2003, Biochemical and biophysical research communications.
[19] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[20] L. Mao,et al. Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons. , 2001, Brain research. Molecular brain research.
[21] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[22] Michael R. Hayden,et al. Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.
[23] E. Simpson,et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.
[24] J. Penney,et al. Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons , 1995, The Journal of comparative neurology.
[25] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[26] D. Rubinsztein,et al. Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.
[27] K. Mikoshiba,et al. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor , 1996, Nature.
[28] Roger L Albin,et al. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons , 1998, Brain Research.
[29] Sten Orrenius,et al. Calcium: Regulation of cell death: the calcium–apoptosis link , 2003, Nature Reviews Molecular Cell Biology.
[30] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[31] M. Gerlach,et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. , 2004, Journal of neural transmission. Supplementum.
[32] L. Raymond,et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease , 2004, Molecular and Cellular Neuroscience.
[33] K. Mikoshiba,et al. Erratum: Intracellular channels (Current Opinion in Neurobiology (1994) 4 (294-303)) , 1994 .
[34] Ilya Bezprozvanny,et al. Deranged neuronal calcium signaling and Huntington disease. , 2004, Biochemical and biophysical research communications.
[35] D. Choi. Calcium: still center-stage in hypoxic-ischemic neuronal death , 1995, Trends in Neurosciences.
[36] L. Raymond,et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease , 2006, Neurobiology of Disease.
[37] R. Albin,et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.
[38] L. Mao,et al. Glutamate cascade to cAMP response element-binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors. , 2002, Molecular pharmacology.
[39] B. Sakmann,et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.
[40] J. Penney,et al. Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. , 1997, Brain research. Molecular brain research.
[41] G. Landwehrmeyer,et al. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[42] R. Llinás,et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Hayden,et al. Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1 , 2003, Neuron.
[44] I. Bezprozvanny,et al. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease , 2006, Neuroscience Letters.
[45] S. Folstein,et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.
[46] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[47] C. Portera-Cailliau,et al. N‐Methyl‐d‐Aspartate Receptor Proteins NR2A and NR2B Are Differentially Distributed in the Developing Rat Central Nervous System as Revealed by Subunit‐Specific Antibodies , 1996, Journal of neurochemistry.
[48] D. Riche,et al. A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon , 1990, Experimental Neurology.
[49] P. Reddy,et al. Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.
[50] M. Salter,et al. NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity , 2001, Current Opinion in Neurobiology.
[51] D. Ferrari,et al. Calcium and apoptosis: facts and hypotheses , 2003, Oncogene.
[52] T. Crow,et al. Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia , 1985, Journal of the Neurological Sciences.
[53] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[54] M. MacDonald,et al. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.
[55] M. Chesselet,et al. Mouse models of Huntington's disease. , 2002, Trends in pharmacological sciences.
[56] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[57] D. Rubinsztein. Lessons from animal models of Huntington's disease. , 2002, Trends in genetics : TIG.